GIST Clinical Trial
Official title:
Exploring the Molecular Mechanism of Secondary Resistance to Imatinib in Gastrointestinal Stromal Tumors Based on KIT Mutation
Imatinib remains suboptimal for recurrence/metastasis and unresectable GIST response rates. With the maturity of genomics and metabolomics, people gradually realize the role of gut microbiota in tumor therapy. The gut microbiota may affect tumor treatment by regulating the tumor microenvironment or the host immune system, and some bacteria can fight tumors by activating the immune system. Growing evidence shows that the effect of tumor therapy is related to the composition of the gut microbiota of patients, and that the composition of the gut microbiota of patients sensitive to drug treatment has certain characteristics, and these characteristics may be used as biomarkers to predict the prognosis of treatment. At present, it remains unclear whether the efficacy of imatinib is related to the gut microbiota in GIST patients. Therefore, precise mining of microbial information and the development of reasonable and feasible microbial interventions are expected to optimize the treatment strategy of GIST to a large extent and provide a basis for individualized treatment of advanced GIST.
Taking Chinese patients with unresectable C-kit9/11-mutated GIST as the research object, the treatment effect was observed after standardized treatment with imatinib mesylate. To explore the relationship between intestinal flora and the efficacy of imatinib treatment, to find new biomarkers to predict the efficacy of imatinib, and to provide reference for individualized treatment of imatinib ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05957367 -
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01770405 -
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
|
N/A | |
| Active, not recruiting |
NCT03556384 -
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
| Completed |
NCT01459757 -
Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
|
N/A | |
| Completed |
NCT00979381 -
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor
|
N/A | |
| Completed |
NCT00399152 -
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
| Completed |
NCT04599660 -
Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)
|
||
| Completed |
NCT05400018 -
Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
|
||
| Recruiting |
NCT03475953 -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04825470 -
Liver Transplantation for Unresectable GIST Liver Metastases
|
N/A | |
| Recruiting |
NCT00687778 -
11C-Acetate PET/CT Non-FDG-Avid Tumors
|
N/A | |
| Completed |
NCT00979329 -
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
|
N/A | |
| Active, not recruiting |
NCT04927260 -
French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients
|
||
| Completed |
NCT03465722 -
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
|
Phase 3 | |
| Completed |
NCT03880617 -
Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
|
||
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Not yet recruiting |
NCT06208748 -
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
|
Phase 2 | |
| Completed |
NCT01323400 -
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
|
Phase 2 | |
| Recruiting |
NCT05804331 -
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
|